Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Terns Pharmaceuticals Inc’s stock clocked out at $3.45, down -5.74% from its previous closing price of $3.66. In other words, the price has decreased by -$5.74 from its previous closing price. On the day, 0.81 million shares were traded. TERN stock price reached its highest trading level at $3.7 during the session, while it also had its lowest trading level at $3.435.
Ratios:
To gain a deeper understanding of TERN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.99 and its Current Ratio is at 32.99. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 31, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $82.
On June 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $16.Mizuho initiated its Buy rating on June 22, 2023, with a $16 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 30 ’24 when Jung Melita Sun bought 2,250 shares for $5.11 per share. The transaction valued at 11,498 led to the insider holds 2,250 shares of the business.
Burroughs Amy L. bought 510 shares of TERN for $2,606 on Nov 30 ’24. The Chief Executive Officer now owns 19,609 shares after completing the transaction at $5.11 per share. On Jan 02 ’25, another insider, Kuriakose Emil, who serves as the Chief Medical Officer of the company, sold 4,481 shares for $5.71 each. As a result, the insider received 25,607 and left with 54,269 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TERN now has a Market Capitalization of 293039200 and an Enterprise Value of -78432952.
Stock Price History:
The Beta on a monthly basis for TERN is -0.29, which has changed by -0.5208334 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, TERN has reached a high of $11.40, while it has fallen to a 52-week low of $3.24. The 50-Day Moving Average of the stock is -20.91%, while the 200-Day Moving Average is calculated to be -48.32%.
Shares Statistics:
It appears that TERN traded 1.61M shares on average per day over the past three months and 1000500 shares per day over the past ten days. A total of 84.92M shares are outstanding, with a floating share count of 63.53M. Insiders hold about 25.20% of the company’s shares, while institutions hold 80.80% stake in the company. Shares short for TERN as of 1740700800 were 6194900 with a Short Ratio of 3.84, compared to 1738281600 on 6454514. Therefore, it implies a Short% of Shares Outstanding of 6194900 and a Short% of Float of 8.02.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Terns Pharmaceuticals Inc (TERN) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.27 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.13 and -$1.24 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is -$1.33, with 9.0 analysts recommending between -$1.13 and -$1.48.
